| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/13/2007 | US7176210 Cannabinoid receptor ligands and uses thereof |
| 02/13/2007 | US7176203 Imidazo-triazine derivatives as ligands for gaba receptors |
| 02/13/2007 | US7176200 Derivatives of sulphonamides, their preparation and use as medicaments |
| 02/13/2007 | US7176198 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| 02/13/2007 | US7176195 Treatment of nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence or bleeding disorders such a hemophilia |
| 02/13/2007 | US7176180 Fusion proteins; immunoglobulins; kits |
| 02/13/2007 | US7176164 1,3-selenazolin derivatives and process for preparing the same |
| 02/13/2007 | US7175997 BMP-11 compositions |
| 02/13/2007 | US7175861 Anti-depression pharmaceutical composition containing Polygala extract |
| 02/13/2007 | US7175853 Therapeutic system which can be moisture-activated |
| 02/13/2007 | US7175850 Formulation for topical non-invasive application in vivo |
| 02/13/2007 | CA2358840C Methods and kits comprising an estrogen agonist/antagonist for improving vascular health |
| 02/13/2007 | CA2295119C Use of a specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing |
| 02/13/2007 | CA2285037C Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same |
| 02/13/2007 | CA2220649C 4-hydroxy-piperidine derivatives |
| 02/08/2007 | WO2007016679A2 Combination immediate release controlled release levodopa and carbidopa dosage forms |
| 02/08/2007 | WO2007016563A2 Alcohol resistant pharmaceutical formulations |
| 02/08/2007 | WO2007016354A1 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 02/08/2007 | WO2007016209A2 Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process |
| 02/08/2007 | WO2007016208A2 1,2-benzisoxazole-3-methane-sulfonic acid ammonium salt |
| 02/08/2007 | WO2007016202A1 Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| 02/08/2007 | WO2007015724A1 Tromethamine salt of valproic acid |
| 02/08/2007 | WO2007015588A1 Piperidine derivative as tachykinin receptor antagonist |
| 02/08/2007 | WO2007015567A1 Cyclic amine compound |
| 02/08/2007 | WO2007015528A1 Agent for treating and/or preventing sleep disorder |
| 02/08/2007 | WO2007015175A2 Use of pp-1 inhibitors to prevent missplicing events |
| 02/08/2007 | WO2007015122A1 Therapy for alzheimer’s disease |
| 02/08/2007 | WO2007015004A2 Novel crystalline v form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form |
| 02/08/2007 | WO2007015003A2 Novel crystalline iii form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form |
| 02/08/2007 | WO2007015002A2 Novel crystalline iv form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form |
| 02/08/2007 | WO2007014970A1 Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia |
| 02/08/2007 | WO2007014946A1 Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
| 02/08/2007 | WO2007014943A2 Therapy for neurological diseases |
| 02/08/2007 | WO2007014843A1 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the gaba-b-receptor |
| 02/08/2007 | WO2007014498A1 Analgesic huperzine and the derivatives thereof |
| 02/08/2007 | WO2007014432A1 Peptide conjugate for oral delivery of hydrophilic peptide analgesics |
| 02/08/2007 | WO2006129318A3 Benzofuran derivatives with therapeutic activities |
| 02/08/2007 | WO2006127899A3 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
| 02/08/2007 | WO2006127898A3 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use |
| 02/08/2007 | WO2006123249A3 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| 02/08/2007 | WO2006100026A8 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists |
| 02/08/2007 | WO2006096439A3 Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| 02/08/2007 | WO2006091702A3 Multimediator dopamine transport inhibitors, and uses related thereto |
| 02/08/2007 | WO2006063837A3 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder |
| 02/08/2007 | WO2006015944A3 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 02/08/2007 | WO2005110490A8 Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
| 02/08/2007 | US20070033669 Semaphorin gene family |
| 02/08/2007 | US20070032653 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. |
| 02/08/2007 | US20070032554 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors |
| 02/08/2007 | US20070032553 Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| 02/08/2007 | US20070032538 Use of compounds |
| 02/08/2007 | US20070032518 Compounds and methods of use |
| 02/08/2007 | US20070032491 Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration |
| 02/08/2007 | US20070032482 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments |
| 02/08/2007 | US20070032466 Drug containing chymase inhibitor as the active ingredient |
| 02/08/2007 | US20070031965 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 02/08/2007 | US20070031904 Mammalian IAP gene family, primers, probes and detection methods |
| 02/08/2007 | US20070031903 Mammalian IAP gene family, primers, probes and detection methods |
| 02/08/2007 | US20070031896 Anti-CCR4 antibodies and methods of use therefor |
| 02/08/2007 | US20070031860 G-protein coupled receptor and uses therefor |
| 02/08/2007 | US20070031821 Screening molecules with anti-prion activity: kits, methods and screened molecules |
| 02/08/2007 | US20070031502 Pharmaceutical composition for the treatment of acute disorders |
| 02/08/2007 | US20070031489 administering sub-analgesic dosage of a mu -opioid agonist selected from morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or salt, and a sub-analgesic dosage of oxycodone, a kappa 2-opioid agonist to prevent sleep apnea while treating pain |
| 02/08/2007 | US20070031443 Methods for treating or preventing skin disorders using CD2-binding agents |
| 02/08/2007 | US20070031441 Immunotherapy based on dendritic cells |
| 02/08/2007 | US20070031416 Use of antibody |
| 02/08/2007 | US20070031396 Method of treating neurological diseases |
| 02/08/2007 | US20070031375 IL-16 antagonist peptides and DNA encoding the peptides |
| 02/08/2007 | US20070031331 Treatment of Disorders |
| 02/08/2007 | CA2617449A1 Peptide conjugate for oral delivery of hydrophilic peptide analgesics |
| 02/08/2007 | CA2617294A1 Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
| 02/08/2007 | CA2617256A1 Cyclic amine compound |
| 02/08/2007 | CA2617164A1 Alcohol resistant pharmaceutical formulations |
| 02/08/2007 | CA2617003A1 Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| 02/08/2007 | CA2616960A1 Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia |
| 02/08/2007 | CA2616685A1 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the gaba-b-receptor |
| 02/08/2007 | CA2616510A1 Cycloalkyl amino-hydantoin compounds and use thereof for .beta.-secretase modulation |
| 02/08/2007 | CA2615574A1 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 02/07/2007 | EP1749884A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 02/07/2007 | EP1749829A1 JNK inhibitors |
| 02/07/2007 | EP1749824A1 Benzodiazepine derivatives, their preparation and the therapeutic use thereof |
| 02/07/2007 | EP1749822A1 Novel cysteine protease inhibitors and their therapeutic applications |
| 02/07/2007 | EP1749821A1 Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments |
| 02/07/2007 | EP1749820A1 Salts of substituted pyrazoline compounds, their preparation and use as medicaments |
| 02/07/2007 | EP1749819A1 (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrates |
| 02/07/2007 | EP1749818A2 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 02/07/2007 | EP1749817A1 Neurogenic pain control agent composition |
| 02/07/2007 | EP1749535A1 Remedy for diabetic neuropathy comprising gelatin gel as carrier |
| 02/07/2007 | EP1749529A1 Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases |
| 02/07/2007 | EP1749525A1 Combination of substituted pyrazolines and anti-addictive agent |
| 02/07/2007 | EP1749523A1 GSK-3 inhibitors |
| 02/07/2007 | EP1749522A2 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 02/07/2007 | EP1749001A1 3-piperidinylisochroman-5-ols as dopamine agonists |
| 02/07/2007 | EP1748995A1 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both |
| 02/07/2007 | EP1748982A1 (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease |
| 02/07/2007 | EP1748981A1 Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide |
| 02/07/2007 | EP1748978A1 Carboxamido opioid compounds |
| 02/07/2007 | EP1651622B1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| 02/07/2007 | EP1506211B1 C-aryl glucoside sglt2 inhibitors and method |
| 02/07/2007 | EP1503765A4 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |